How I treat transplant-eligible patients with myelofibrosis
N Kröger, C Wolschke, N Gagelmann - Blood, 2023 - ashpublications.org
Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …
[HTML][HTML] State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
DP McLornan, I Yakoub-Agha, M Robin… - …, 2019 - ncbi.nlm.nih.gov
Advances in understanding the pathogenesis and molecular landscape of myelofibrosis
have occurred over the last decade. Treating physicians now have access to an ever …
have occurred over the last decade. Treating physicians now have access to an ever …
How I treat myelofibrosis after failure of JAK inhibitors
A Pardanani, A Tefferi - Blood, The Journal of the American …, 2018 - ashpublications.org
The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
M Tiribelli, F Palandri, E Sant'Antonio… - Bone Marrow …, 2020 - nature.com
Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
Myelofibrosis: to transplant or not to transplant?
R Devlin, V Gupta - Hematology 2014, the American Society of …, 2016 - ashpublications.org
Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …
How we manage myelofibrosis candidates for allogeneic stem cell transplantation
N Polverelli, M Farina, M D'Adda, E Damiani, L Grazioli… - Cells, 2022 - mdpi.com
Moving from indication to transplantation is a critical process in myelofibrosis. Most of
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …
Novel therapies in myelofibrosis: beyond JAK inhibitors
JA Waksal, J Mascarenhas - Current Hematologic Malignancy Reports, 2022 - Springer
Abstract Purpose of Review To discuss the current treatment paradigm, review novel targets,
and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in …
and summarize completed and ongoing clinical trials that may lead to a paradigm shifts in …
[HTML][HTML] Allogeneic stem cell transplantation in myelofibrosis
Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …
Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond
CN Harrison, DP McLornan - Hematology 2014, the American …, 2017 - ashpublications.org
Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly,
constitutional symptoms, ineffective hematopoiesis, and an inherent risk of leukemic …
constitutional symptoms, ineffective hematopoiesis, and an inherent risk of leukemic …
Allogeneic stem cell transplantation for myelofibrosis in 2012
DP McLornan, AJ Mead, G Jackson… - British journal of …, 2012 - Wiley Online Library
Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …